Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · DCAL

DCAL

HealthcarePharmaceuticals & Biotechnology₹1901 cr market cap
₹118.53 ▼ -2.16% today As of 19 Nov 2026
52-week low ₹121.1552-week high ₹264.95

-54.3% from the 52-week high · +0.0% above the low

Dishman Carbogen Amcis Ltd. is a manufacturing company, which engages in the provision of outsourcing services for the pharmaceutical industry. The company is headquartered in Ahmedabad, Gujarat and currently employs 1,168 full-time employees. The company went IPO on 2017-09-21. The firm's segments include CRAMS and Vitamin - D, Bulk Drugs, Quats, Specialty Chemicals and traded goods. The firm assists pharma companies through various stages of drug development from process research and development to late-stage clinical and commercial manufacturing facilities, along with the supply of active pharmaceutical ingredients (APIs) and intermediates. The firm has manufacturing and research facilities in India, Switzerland, France, Netherlands, United Kingdom and China. The firm's subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd., CARBOGEN AMCIS Holding AG and Dishman Biotech Ltd.

The short version. DCAL reported revenue of ₹507 crore for Sep 2026, down 22.4% from a year earlier. Net profit was ₹-67 crore (down 203.1% year on year). Return on equity was 1.5% in Mar 2026. Promoter holding was 59.32% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

DCAL trades 54.3% below its 52-week high and 0.0% above its 52-week low.

Change over period: —

1M-16.9%
3M-29.7%
6M-42.6%
1Y-51.3%

2 · The business

Is it growing?

Sales, year on year-22.4%

Sep 2026 revenue of ₹507 cr.

Profit, year on year-203.1%

Sep 2026 net profit of ₹-67 cr.

Net margin-13.2%

23.2 pts lower than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue507678851720653708716682
Net profit-67-5822-136523435
Net margin %-13.2-8.52.6-1.810.03.36.00.7
EPS (₹)-4.26-3.691.39-0.834.161.492.750.3

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue29322712261624132141191220442059
Net profit973-153-3018-165180210
Net margin %3.30.1-5.9-1.20.8-8.68.810.2
EPS (₹)6.220.21-9.79-1.91.15-10.5311.4913.03

3 · The quality

How well does it turn capital into profit?

Return on equity was 1.5% in Mar 2026; debt to equity is 0.42.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %1.50.1-2.7-0.5
Return on capital %2.92.2-0.00.4
EBITDA margin %20.717.311.712.8
Net margin %3.30.1-5.8-1.2

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR7.0%8.9%
Profit CAGR——
Debt to equity0.42
Interest cover1.6x
Current ratio1.23
P/E ratio97.4

4 · The owners

Who holds it, and are they adding?

Promoter holding59.32%

Unchanged over 8 quarters.

Foreign institutions6.97%

Down 1.78 pts over 8 quarters.

Domestic institutions1.66%

Up 0.24 pts over 8 quarters.

Mutual fund schemes3

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter59.3259.3259.3259.3259.3259.3259.3259.320.0
FII8.759.499.938.077.667.456.866.97-1.78
DII1.421.261.271.371.271.632.071.66+0.24
Public30.5129.9329.4731.2331.7531.631.7532.06+1.55

Mutual fund holdings · Oct 2026

3 schemes hold this stock

3 the month before.

  • HSBC Flexi Cap Fund0.57% of NAV
  • Motilal Oswal BSE Healthcare ETF0.06% of NAV
  • Bandhan BSE Healthcare Index Fund0.06% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for DCAL are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about DCAL

What is the DCAL share price?

DCAL (DCAL) last closed at ₹118.53, down 2.16% on the day. Its 52-week range is ₹121.15 to ₹264.95.

What is the market cap of DCAL?

DCAL has a market capitalisation of about ₹1,901 crore. Its price-to-earnings ratio is 97.4.

How are DCAL's latest results?

DCAL reported revenue of ₹507 crore for Sep 2026, down 22.4% from a year earlier. Net profit was ₹-67 crore (down 203.1% year on year). Return on equity was 1.5% in Mar 2026. Promoter holding was 59.32% in Sep 2026, up 0.00 points over 8 quarters.

Who owns DCAL?

As of Sep 2026, shareholding was: Promoter 59.32%, FII 6.97%, DII 1.66%, Public 32.06%.

How many mutual funds hold DCAL?

3 mutual fund schemes held DCAL in October 2026. That compares with 3 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 12 Sep 2019 · Final Dividend - Rs. 0.2

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.